Cordblood contains blood stem cells and is routinely used to treat severe diseasesof the blood and immune system. The treatment is similar to bone marrow stem celltherapy and the most common use of cord blood is sibling donation for thetreatment of childhood leukaemia.
NextCellowns the Cellaviva biobank, which has been helping pregnant parents savestem cells in connection with childbirth since 2015. The umbilical cord bloodthat is saved is the blood that remains in the placenta and umbilical cordafter the baby is born and the cord has been cut. In addition, a piece of theumbilical cord is also collected to grow connective tissue-forming stem cells.Haematopoietic stem cells can mature into all types of blood cells and immunecells, while connective tissue stem cells can mature into other tissues such ascartilage, fat and bone.
“ Thepurpose of preserving stem cells is not the saving itself, but to have rapidaccess to the highest quality stem cells in case of serious disease. Ourorganisation contributes to the development of new therapies and the expansionof treatment options for affected patients. Ultimately, it's about savinglives," says Mathias Svahn, vd NextCell.
Thecollection of stem cells from the umbilical cord does not alter the birthingprocess in any way and is risk-free. Currently, there are over 80 healthconditions with cord blood stem cells as an approved treatment option. In addition,experimental treatments using cord blood and cord tissue stem cells are beingevaluated for conditions such as cerebral palsy and type 1 diabetes. NextCellis conducting its own clinical trials with cells from donated umbilical cordsfor the treatment of type 1 diabetes and severe pneumonia caused by COVID-19.
SofieFalk-Jansson, Commercial Director
Tel: 08-735 2010
For more information about NextCell PharmaAB, please contact:
Mathias Svahn, CEO
Patrik Fagerholm, CFO
About NextCell Pharma AB
NextCell is a phase II cell therapy company withthe drug candidate ProTrans for the treatment of type 1 diabetes. The focus isto take ProTrans to market approval via a Phase III study. ProTrans is inaddition to diabetes, used in two clinical trials for Covid-19, in Örebro andMontreal (Canada). The company is in the processes of establishing its own GMPfacility for production of ProTrans. The GMP facility is expected to be readyfor production of smaller quantities of ProTrans in 2023. NextCell furthermoreowns 8,5% in FamicordTX, a CAR-T start-up in oncology and 100 % of Cellaviva,Scandinavia's largest stem cell bank for family saving stem cells fromumbilical cord blood and umbilical cord tissue with permission from the SwedishHealth and Social Care Inspectorate (IVO).